• Working closely with FSP vendors: how much oversight do you need?
• Benefits and challenges of moving to an FSP outsourcing model
• Comparing vendor management strategies between pharma and biotechs: do you need a different
approach?
• Why is FSP becoming a popular outsourcing model: what benefits can this offer sponsors?
MODERATOR:
Rich Polgar, Managing Director, Danforth Advisors
PANELLISTS:
Melanie Goodwin, Director, Clinical Outsourcing,
Immunocore
Russell Bland, Director, Clinical Outsourcing and
Innovation, Jazz Pharmaceuticals
Terry Katz, Senior Director, Biostatistics and Data
Management Planning and Functional Excellence, Daiichi
Sankyo, Inc